Caribou Biosciences (CRBU) Competitors $1.79 +0.08 (+4.68%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$1.76 -0.03 (-1.40%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. ANAB, GHRS, DNA, NAGE, TNGX, STOK, VIR, AMLX, DAWN, and DNTHShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include AnaptysBio (ANAB), GH Research (GHRS), Ginkgo Bioworks (DNA), Niagen Bioscience (NAGE), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Vir Biotechnology (VIR), Amylyx Pharmaceuticals (AMLX), Day One Biopharmaceuticals (DAWN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Its Competitors AnaptysBio GH Research Ginkgo Bioworks Niagen Bioscience Tango Therapeutics Stoke Therapeutics Vir Biotechnology Amylyx Pharmaceuticals Day One Biopharmaceuticals Dianthus Therapeutics AnaptysBio (NASDAQ:ANAB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Is ANAB or CRBU more profitable? AnaptysBio has a net margin of -107.66% compared to Caribou Biosciences' net margin of -1,490.84%. Caribou Biosciences' return on equity of -55.70% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Caribou Biosciences -1,490.84%-55.70%-45.35% Which has better valuation and earnings, ANAB or CRBU? AnaptysBio has higher revenue and earnings than Caribou Biosciences. AnaptysBio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$123.16M4.57-$145.23M-$4.48-4.49Caribou Biosciences$9.99M16.66-$149.10M-$1.62-1.10 Which has more risk & volatility, ANAB or CRBU? AnaptysBio has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.55, indicating that its share price is 155% more volatile than the S&P 500. Do analysts recommend ANAB or CRBU? AnaptysBio presently has a consensus price target of $46.13, indicating a potential upside of 129.36%. Caribou Biosciences has a consensus price target of $6.67, indicating a potential upside of 272.44%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ANAB or CRBU? In the previous week, AnaptysBio had 22 more articles in the media than Caribou Biosciences. MarketBeat recorded 26 mentions for AnaptysBio and 4 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.87 beat AnaptysBio's score of 0.91 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals hold more shares of ANAB or CRBU? 77.5% of Caribou Biosciences shares are held by institutional investors. 33.5% of AnaptysBio shares are held by insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryCaribou Biosciences beats AnaptysBio on 9 of the 17 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.04M$2.99B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-1.1019.9630.4025.31Price / Sales16.66346.50448.16101.62Price / CashN/A40.7837.7258.50Price / Book0.647.658.296.01Net Income-$149.10M-$54.75M$3.26B$265.10M7 Day Performance-4.79%0.95%1.56%1.39%1 Month Performance9.82%8.12%3.75%2.43%1 Year Performance-3.76%10.97%40.94%24.74% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences3.2027 of 5 stars$1.79+4.7%$6.67+272.4%-3.2%$159.04M$9.99M-1.10100News CoverageEarnings ReportANABAnaptysBio3.0911 of 5 stars$24.23-1.9%$47.13+94.5%-40.4%$725.40M$91.28M-5.00100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGHRSGH Research2.2068 of 5 stars$13.44-2.2%$32.00+138.1%+23.6%$714.87MN/A-17.0110Positive NewsEarnings ReportDNAGinkgo Bioworks0.8967 of 5 stars$13.62+11.7%$8.50-37.6%N/A$713.50M$227.04M-1.49640News CoverageEarnings ReportNAGENiagen Bioscience1.2937 of 5 stars$9.64+6.6%$13.22+37.1%N/A$712.08M$99.60M56.71120Earnings ReportAnalyst ForecastAnalyst RevisionTNGXTango Therapeutics1.9445 of 5 stars$6.59+0.9%$10.50+59.3%-20.5%$707.81M$40.99M-5.4090Gap UpSTOKStoke Therapeutics4.1142 of 5 stars$13.14+1.8%$25.80+96.3%-6.3%$704.85M$36.56M16.63100News CoverageEarnings ReportVIRVir Biotechnology2.8635 of 5 stars$5.10+1.4%$30.25+493.1%-48.5%$695.34M$74.21M-1.21580Earnings ReportAnalyst RevisionAMLXAmylyx Pharmaceuticals3.012 of 5 stars$7.96+3.1%$11.75+47.6%+314.1%$687.72M-$1.27M-2.56200Earnings ReportDAWNDay One Biopharmaceuticals2.8217 of 5 stars$6.74+1.4%$29.00+330.3%-54.5%$674.06M$131.16M-9.4960DNTHDianthus Therapeutics1.8104 of 5 stars$21.50+4.4%$53.00+146.5%-24.8%$662.17M$6.24M-7.4780News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies AnaptysBio Competitors GH Research Competitors Ginkgo Bioworks Competitors Niagen Bioscience Competitors Tango Therapeutics Competitors Stoke Therapeutics Competitors Vir Biotechnology Competitors Amylyx Pharmaceuticals Competitors Day One Biopharmaceuticals Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access